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Abstract
Endobronchial coils are an additional treatment option for 
lung volume reduction in patients with severe emphysema. 
Patient selection should be focused on patients with severe 
emphysema on optimal medical therapy and with evidence 
of severe hyperinflation. The technique is suitable in a broad 
range of patients with emphysema; however, patients with 
paraseptal emphysema, large focal (giant) bullae, significant 
co-morbidity and airway-predominant disease should be 
avoided. Treatment involves placing between 10 and 14 
coils by bronchoscopy in the selected treatment lobe, with 
2 lobes being treated sequentially. Lobe selection for treat-
ment should be based on quantitative computed tomogra-
phy, and the lobes with the greatest destruction should be 
targeted (excluding the right middle lobe). The treatment 
results in an improvement in pulmonary function, exercise 
performance and quality of life, particularly in patients with 
severe hyperinflation (residual volume > 200% predicted) 
and upper-lobe heterogeneous emphysema, but will also be 
of benefit in lower-lobe predominant and homogeneous 
emphysema. Finally, it has an acceptable safety profile, al-
though special attention has to be paid to coil-associated 
opacity which is an inflammatory response that occurs in 
some patients treated with endobronchial coils.
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Endoscopic lung volume reduction is a realistic treat-
ment option for selected patients with severe emphysema 
[1, 2]. Different endoscopic lung volume reduction ap-
proaches have been developed to accommodate the differ-
ent emphysema phenotypes, with both endobronchial one-
way valve treatment and endobronchial coil treatment be-
ing the most intensively investigated [3–6]. These therapies 
are also recognised in the recent chronic obstructive pul-
monary disease (COPD) GOLD recommendations [7]. The 
endobronchial coils are “non-blocking” devices which are 
delivered by bronchoscopy into the sub-segmental airways. 
Unlike one-way endobronchial valves, the endobronchial 
coils are also effective in patients with interlobar collateral 
ventilation and, thus, work independent of this phenome-
non. Furthermore, endobronchial coils do not induce lobar 
atelectasis and, hence, cause minimal reduction on the gas 
exchange area of the treated lobe. The coils are made from 
shape memory nitinol (a nickel-titanium alloy) wire (Fig. 1). 
About 10–14 coils are placed at each treatment under fluo-
roscopic guidance, with the objective of treating 2 contra-
lateral lobes in 2 separate procedures, with the contralat-
eral lobe being treated 4–8 weeks later. The procedure is 
preferably performed under general anaesthesia, and the 
patients are hospitalized for at least 1 night for observation 
after the procedure. However, this can vary widely with lo-
cal practice. This article provides detailed guidance by an 
international panel of experts experienced in this therapy 
regarding patient selection, peri-procedural care and tech-
nical guidance on performing the procedure. We have also 
addressed the management of procedural complications.
Summary of Clinical Evidence
Early feasibility studies and randomized clinical trials 
have shown consistent benefits with improvements in 
pulmonary function, quality of life and 6-minute walking 
distance test for treated patients in comparison with con-
trol patients who received optimal medical management 
of their emphysema. Table 1 provides an overview of the 
most relevant endobronchial coil trials published [8–17].
Mechanisms of Action
Understanding the mechanisms of action is important, 
as this may facilitate better patient selection, enable opti-
mization of the implantation technique and drive the de-
velopment of new coils, perhaps even adjusted to the in-
dividual needs and characteristics of a patient. Differing 
views exist, and one possibility is that the nitinol wires, 
following deployment, return to their predetermined 
shape, distorting the airways and thereby compressing the 
diseased tissue and achieving re-tensioning of the diseased 
airway network to decrease air-trapping and hyperinfla-
tion. Additionally, improved elastic recoil and hyperinfla-
tion are thought to improve diaphragm and inspiratory 
muscle function [18]. Finally, well-placed coils may theo-
retically improve elastic recoil forces locally and, thus, re-
duce overall inhomogeneity of ventilation. Unfortunately, 
no study has so far systematically investigated these differ-






Fig. 1. The PneumRx endobronchial coil system. The system con-
sists of a single-patient use delivery system with a cartridge, cath-
eter, guidewire, forceps and coils (with permission from Pneum-
Rx, CA, USA). The coil is available in 3 lengths (100, 125 and 150 
mm) to accommodate the different airways. The distal and proxi-
mal ends of the coil are designed to reside in sub-segmental air-
ways. 




(CT) scan study measured in- and expiratory lobe vol-
umes and luminal areas of segmental bronchi, before and 
after coil treatment, in 30 severe emphysema patients [19]. 
In the treated segmental bronchia, the cross-sectional lu-
men decreased significantly during inspiration and tend-
ed to increase during expiration. Volumes of the treated 
segments correlated with the treated segmental bronchial 
lumina in expiration (r = 0.80, p < 0.001). The authors sug-
gest that the data of the study are in support of the current 
understanding of coil effects, which claim that they stabi-
lise and stiffen the lung parenchyma, thus compensating 
for the loss of elasticity in the lung interstitium and con-
sequently reducing bronchial motility and collapsing. A 
further study by Palamidas et al. [20] evaluated lobar vol-
umes in a randomised controlled study. Target lobar vol-
umes were decreased, and compensatory hyperinflation 
of the untreated ipsilateral lobes was observed. Hence, 
there was no dramatic reduction in total lung capacity 
(TLC). There were strong correlations between reduction 
in volumes of the treated lobes and changes in pulmonary 
function. The greatest effects appeared to occur in patients 
who developed inflammatory coil-associated opacities. 
This inflammatory process itself induces localised fibrosis 
and, hence, volume reduction with improvements in pul-
monary function.
Patient Selection
Patient selection is a critical and very important part 
of the treatment for attaining the best outcomes. Impor-
tant selection criteria include the following:
Table 1. Studies on lung volume reduction coil treatment for emphysema
First author [ref.], 
year


































































retrospective 40 6 months 24.7% –14.5% 48 m –10.4





















1 year 8% 
(CI 3 to 13)
−9% 
(CI −12 to −5)
–0.05% 
(CI –10 to 10)
−9.1 




























12 months 3.8% 
(CI –6.3 to 16.1)
–0.41 L
(CI 0.57 to –0.25)
10.3 m
(CI –33.0 to 45.0)
–8.1 
(CI –10.2 to –6.0)
Values are changes from baseline with ± standard deviation or range or 95% CI in parentheses. Between-group differences for coil versus usual care (in 
the RCTs) are not shown. RCT, randomized controlled trial; FEV1, forced expiratory volume in the first second; RV, residual volume; 6MWD, 6-minute 
walking distance; SGRQ, St George’s Respiratory Questionnaire Response; hetero, heterogeneous distribution of emphysema; mixed, heterogeneous and 




The key parameters are evidence of severe airflow ob-
struction (forced expiratory volume in the first second 
[FEV1] ≤45% predicted) and the presence of severe hy-
perinflation. For this treatment modality, hyperinflation 
should be measured by body plethysmography. Patients 
with a residual volume (RV) > 200% predicted are deemed 
the best responders. In some situations, patients with an 
RV between 175 and 200% predicted may be considered 
for treatment if other measures of hyperinflation are fa-
vourable, i.e., RV/TLC ratio ≥0.58 [21, 22].
Symptoms and Exercise Performance
Patients should be highly symptomatic with respect to 
dyspnoea (modified British Medical Research Council 
[mMRC] > 1) and restricted in their exercise performance 
(6-minute walking distance < 450 m). However, if a pa-
tient has significant symptoms of concurrent chronic air-
ways disease, such as frequent cough, severe bronchial 
hyper-responsiveness, sputum production and/or fre-
quent exacerbations, the patient should not be considered 
for coil treatment. Also, patients with a very low exercise 
tolerance (6-minute walking distance < 140 m) may not 
represent the ideal candidates for therapy.
Emphysema Morphology
Centrilobular to moderate panlobular emphysema is 
the best emphysema phenotype for coil treatment. Severe 
panlobular emphysema, giant bullae and paraseptal em-
physema are morphological patterns of emphysema that 
are not suitable for treatment with endobronchial coils. 
Computerised quantitative CT analysis using densitom-
etry should be utilised to more accurately assess the 
amount of parenchymal destruction and guide optimal 
selection of the treatment site. Potential sites of treatment 
are where there is lobar destruction of 20–80% at the –950 
HU threshold on a low (or “soft”) kernel reconstructed 
thin-slice (1 mm) high-resolution CT. The lobes with the 
greatest degree of destruction should be targeted. Endo-
bronchial coils can be used independent of collateral ven-
Fig. 2. Coils implanted in homogeneous emphysema. Chest X-ray 
in a patient with homogeneous emphysema and severe hyperinfla-
tion. Twelve coils have been implanted in the right upper lobe and 
10 in the left upper lobe. The distribution of the coils is around the 
upper part of the hilum, keeping enough distance to the pleurae. 
A small coil-associated opacity is seen around the most inferiorly 
located coil on the left side. 
Keep at ostium of the
target segment
Advance guidewire until the












Fig. 3. Optimal position of the bronchoscope and guidewire. a The bronchoscope is placed at the ostium of the 
target segment in a fixated manner. b The guidewire is advanced until the first marker is just outside the bron-
choscope. In this position, mostly a coil of 125 mm can be placed in the target area of the lung (see Fig. 4). 




tilation, and, hence, fissure integrity is not a crucial as-
sessment. However, the authors recommend a more ho-
listic approach when assessing patients and would 
recommend a full evaluation followed by a multi-disci-
plinary discussion to ensure that the patient receives the 
best treatment option for their individual situation [4]. 
Furthermore, emphysema patients with both a homoge-
neous or heterogeneous emphysema distribution can be 
treated. Similarly, both upper lobe or lower lobe emphy-
sema may be treated.
Coil Placement
The Lung Volume Reduction Coil System
The PneumRx endobronchial coil system (Pneum-
Rx, CA, USA) is a two-part system consisting of coils 
and a delivery system (Fig. 1). The delivery system com-
prises a guidewire, a delivery catheter, locking grasping 
forceps and a loading cartridge. The forceps are used to 
grasp and fixate the proximal end of the coil, which is 
then pulled into the loading cartridge. The loading car-
tridge is slid over the forceps and the coil is effectively 
straightened when it is pulled into the cartridge. Coils 
are composed of nitinol, a biocompatible super-elastic 
material that is shaped in a special pre-determined dou-
ble loop. The distal and proximal ends of the coil are 
terminated with a smooth atraumatic ball. The coil is 
available in 3 lengths (100, 125 and 150 mm) to accom-
modate different-sized airways. A coil is delivered 
straight into an airway and switches back to its pre-de-
termined shape upon deployment. The tools require a 
therapeutic bronchoscope with a minimum 2.8-mm 
working channel. 
Box 1. Key points in patient selection
Medical history/co-morbidity




COPD according to GOLD, with FEV1 <45% predicted
Presence of emphysema on HRCT scan, showing tissue destruction with percentage voxel density less than 
–950 HU between 20 and 80%
Severe hyperinflation assessed by body box: RV/TLC >58% and RV >200% predicted (absolute minimal  
criteria)
Dyspnoea scoring ≥2 mMRC
Optimal pharmacological and non-pharmacological treatment, including abstinence from smoking during 
at least 6 months, and a regular exercise programme
Fit enough to undergo the bronchoscopic procedure, including a 6-minute walking distance >140 m
Exclusion
Severe gas exchange abnormality: PaCO2 >7.3 kPa (55 mm Hg) and/or PaO2 <6.7 kPa (50 mm Hg) (room 
air)
Recurrent airway infections ≥3 times/year
Significant chronic bronchitis, including asthmatic bronchitis and Asthma COPD Overlap (ACO)
Radiological abnormalities like:
– Severe bronchial wall thickening
– Bronchiectasis
– Giant bullae >1/3 lung volume
– Significant presence of paraseptal emphysema
– Pulmonary nodules which are suspicious for lung cancer or active infection
– Significant fibrotic lesions and signs of interstitial lung disease
– Previous lung volume reduction surgery or lobectomy/pneumonectomy
Pulmonary hypertension defined by right ventricular systolic pressure >50 mm Hg via echocardiogram
Evidence of other disease(s) which may compromise survival of the subject or reduce the benefits of coil 
treatment
Medication like antiplatelet or anticoagulant therapy which cannot be stopped prior to the procedure
Chronic immunomodulatory therapy; e.g. methotrexate or anti-TNF to treat an autoimmune disorder, 
prednisolone ≥10 mg/day, CVID (common variable immunodeficiency), maintenance antibiotics




The lung volume reduction coil placement is prefera-
bly performed under general anaesthesia, and the patients 
are generally hospitalized for 1 night of observation fol-
lowing the procedure (this can vary widely with local 
practice, however). The coil procedure is a sequential 
treatment, with 1 lobe treated initially and the target lobe 
in the contralateral lung treated 4–8 weeks later. About 
10–14 coils are placed in the target lobes under fluoros-
copy (Fig. 2). The procedure is performed under fluoro-
scopic guidance. 
First, the flexible guidewire, which has an atraumatic 
tip that serves as a guide for the delivery catheter, is used 
to identify suitable airways for treatment. It has radio 
opaque markers that correspond to the 3 different coil 
sizes and facilitate the choice of the appropriate coil 
length. The guidewire and catheter are inserted together 
into the instrument channel of the bronchoscope. The 
bronchoscope is advanced to the ostium of one of the 
sub-segmental airways in the treatment lobe (Fig.  3a). 
Afterwards, the guidewire is advanced into one of the 
sub-segmental airways and advanced as far as the pleura. 
This allows estimation of the target airway length. The 
wire is then withdrawn back from the pleural edge until 
a safe distance is guaranteed (best 25–40 mm). The cath-
eter is then gently advanced over the guidewire, again 
under fluoroscopy. In the majority of patients, it is only 
necessary to advance the catheter over the guidewire un-
til just over one visible marker (Fig. 3b). This distance 
comfortably allows the placement of a 125-mm length 
coil and ensures that wherever possible the coil is placed 
in the mid third of the lung and not in the periphery 
(Fig. 4). The catheter should not be advanced against re-
sistance. Once the catheter has been advanced to the de-
sired position, the guidewire is withdrawn until it is 
aligned with the catheter to measure the optimal coil size. 
The guidewire can then be withdrawn and the fluoros-
copy switched off.
After loading the cartridge with the right sized coil, the 
cartridge is coupled with the catheter. The forceps and 
coil are then advanced through the catheter. A guide 
mark on the catheter advises the operator when the coil 
is approaching the distal end of the catheter, and the flu-
oroscopy should be recommenced at this stage. The coil 
is advanced until the ball and the first half loop of the coil 
are protruding from the catheter. This allows the coil to 
be anchored into position, and then the coil is deployed 
by withdrawing the catheter. As the coil is withdrawn, it 
reverts to its original shape, and once both the coil and 
the distal end of the grasping forceps are outside the cath-
eter sheath, a small amount of reverse tension is placed on 
the grasping forceps, after which they are opened to re-
lease the coil: the coil will then jump out of the forceps 
(Fig. 5 shows all coil deployment steps). The coil place-
ment process can be reversed to reposition or retrieve the 
coil, if necessary (Fig. 6). The authors believe that this is 
only necessary at max for 1 or 2 coils and best to be per-
formed at the end of the procedure if a coil sticks out of 
the individual segmental or lobar airways. Fluoroscopy is 
again terminated after verifying that the coil has been ap-
propriately deployed. The whole process is repeated until 
10–12 coils have been deployed for upper lobe treatment 
and 10–14 coils for lower lobe treatment. The coils are 
preferably not placed in the segments RB4/5 and LB5 for 
safety reasons and lack of efficacy and safety data for these 
positions.
The absolute DON’Ts of this procedure are:
1. Use the catheter to push the guidewire forward or ad-
vancing the catheter distally beyond the guidewire 
(Fig. 7).
2. Advance the catheter against significant resistance.
3. Placing the coil too distally (outside ball within 25 mm 
of the pleura), or proximally (inside ball outside the 
segmental ostium). 
4. Trying to release the coil by unlocking the forceps, 
while the forceps are still inside the catheter.
5. Placing 2 coils in the same segmental bronchus. 
Fig. 4. Target area for coils. The ideal target area of coils is in the 
mid third of the lung; not too peripherally (the best distance to the 
pleura is 25–40 mm) and not too centrally (not proximally of the 
segmental ostium). 




6. Losing the position of the tip of the catheter (by mov-
ing to a more central position) during the deployment 
phase of the coil.
7. Performing any of the coil placement steps without 
fluoroscopy.
Patient Management and Bronchoscopy
Patient management starts with selecting appropriate 
patients. A multi-disciplinary team (pulmonology, radi-
ology, thoracic surgery and pulmonary rehabilitation 
knowledge) should be involved in selecting the most ap-
propriate treatment for an individual patient. Frequently, 
pharmacological and non-pharmacological treatment 
need to be optimized, substantially delaying or prevent-
ing the start of a coil treatment. It is important to ensure 
that the patient is not a frequent exacerbator, particularly 
due to infectious bronchitis; hence, new patients may 
need to be monitored for a period prior to being consid-
ered for treatment. 
The patient should continue their routine medica-
tions. The procedure is best performed under general an-
aesthesia using local guidelines on both airway access 
(flexible endotracheal tube + positive pressure ventila-
tion, or rigid bronchoscopy + jet ventilation) and anaes-
thetics used. Intubation with an un-cuffed endotracheal 
tube (Rusch or Portex) is recommended when the proce-
dure is being performed under conscious sedation.
After introduction of the bronchoscope, the airways 
are inspected, and bronchial secretions are collected for 
microbial cultures. Coils are placed according to the step-
by-step procedure described above. After disconnecting 
the forceps from a coil, leave the catheter in the entrance 
of the treated segmental bronchus, ready to support the 
next coil placement nearby that position, with as little ma-
nipulation as possible, in this way avoiding oedema, se-
cretions, haemorrhage and bronchoconstriction. Some-
times, mild or moderate haemorrhage may occur, which 
mostly responds well to gentle suction. The procedure 
time varies between 20 and 45 min and a fluoroscopy time 
of 5–15 min, depending on patient factors, anaesthesia 
technique and physician experience with the technique. 
Box 2. Step-by-step coil placement
1. Navigate the bronchoscope to the target airway and position at the ostium of a segmental airway.
2. Insert both the catheter and guidewire into the working channel of the bronchoscope.
3. Advance and navigate the guidewire into the distal targeted airway under fluoroscopy guidance. 
4. Estimate position of pleural edge and length of the airway with the guidewire and then retract the 
guidewire so that it is either far enough from the pleural edge (25–40 mm) or a maximum of 1.25–1.5 
fluoroscopy markers distal from the tip of the bronchoscope (to accommodate a 125-mm coil).
5. Hold the guidewire position fixed relative to the bronchoscope and advance the catheter distally but  
not beyond the tip of the guidewire.
6. Once the catheter is in the desired position, withdraw the guidewire tip until it is aligned with the tip  
of the catheter.
7. Use the radiopaque markers on the guidewire to measure the airway length.
8. Remove the guidewire from the catheter while maintaining the catheter position.
9. The desired size coil can be loaded into the cartridge (1 radio-opaque marker or fractionally less = 
 
if more than 2 markers consider using 150-mm coil).
10. Connect the cartridge to the Luer-lock hub of the catheter and lock into place. 
11. Deliver the coil into the catheter by advancing the forceps and coil.
12. Align the distal end of the coil with the distal end of the catheter.
13. Position the coil using fluoroscopy.
14. Have an assistant hold the bronchoscope fixed relative to the patient.
15. Deploy the coil using fluoroscopy by withdrawing the catheter with one hand, while holding the coil 
position fixed with the forceps using the other hand.
16. Verify the position of the coil under fluoroscopy and release the coil by unlocking the forceps under 
gentle traction.
17. Remove the forceps from the catheter.
18. The catheter may continue to be used to repeat steps 2–17 to deploy additional coils. The coil can be 
removed or repositioned by reversing this implantation process.
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After extubation, the patient is stabilized routinely and 
monitored for vital functions in the recovery room for at 
least 2 h. The patient is treated with at least 5 days of oral 
steroids and prophylactic antibiotics. The antibiotics can 
be adjusted according to bacterial sensitivities from pre-
vious cultures or the bronchial washings obtained during 
the procedure. A post-procedure chest radiograph should 
be performed both to record baseline coil position and to 
exclude a pneumothorax (very rare in experienced cen-
tres). If no complications have occurred, the patient is 
discharged from the hospital, with the second bronchos-
copy being scheduled within 6–8 weeks. 
Adverse Events
Adverse events generally occur in the peri-procedural 
and post-procedural period, and frequency returns to 
baseline in the months following the second procedure 




Fig. 5. Coil deployment. Fluoroscopic series of a coil placement in 
the left upper lobe. Note that the bronchoscope is positioned all the 
time at the same position at the ostium of the segment. a Introduc-
tion of the guidewire up to one marker plus 1/3 length of the guide-
wire and 25–40 mm away from the pleura. Now, also the appropri-
ate coil length can be chosen (in this case 125 mm). b The catheter 
is advanced over the guidewire (which is held in a stable position) 
just up to the distal end of the guidewire. c The guidewire is re-
moved, leaving the catheter in place with just a radio-opaque 
marker being visible at the distal end. d Introduction of the coil, 
which is being pushed forward using the biopsy forceps until it 
reaches the distal end (marker) of the catheter. e The coil is still 
being pushed forward until the first half loop of the coil has been 
deployed. f From this point, the catheter is withdrawn, keeping the 
coil in the exact position, which requires gentle feeding/pushing of 
the biopsy forceps in the distal direction. g The catheter is now 
fully withdrawn (allowing full coil deployment), also over the bi-
opsy forceps head to allow release of the coil. h Gentle backward 
force is applied to both the catheter and biopsy forceps, thereby 
retracting the coil system about 2 cm back, also to facilitate coil 
release. i In this position, the biopsy forceps is opened, and the coil 
will jump out, back to the previous position. Repeat these steps for 
the next coils to be placed.




of pneumonia in the coil versus usual care group, which 
is identical to earlier reports [17, 23]. A number of these 
pneumonias appeared to be non-infectious in nature and 
are now considered secondary to the force of the coils on 
the lung tissue causing an inflammatory response. This 
response results in dense consolidations, mimicking an 
organizing pneumonia, and are referred to as “coil-asso-
ciated opacity” (CAO) (Fig. 8). CAO thus behaves as a 
pneumonia, with chest discomfort, dyspnoea, low oxygen 
saturation, cough, elevated inflammatory markers and 
consolidations around some of the coils on a chest X-ray. 
Fever and purulent sputum are less prominent and may 
be absent. Patients should be treated for pneumonia, with 
the addition of oral corticosteroids (0.5 mg/kg). After re-
covery, the patients who experienced a CAO normally are 
the best responders to the coil treatment due to signifi-
cant reduction in treated lobar volume.
In the RENEW trial, there were 2 direct procedure-
associated deaths; one patient died because of an intra-
procedural pulmonary haemorrhage, and another patient 
died of respiratory failure 6 days following the second coil 
procedure [11]. In a 1-year single-centre retrospective 
analysis of 86 patients with severe COPD, totally 4 pa-
tients passed away within the first 3 months after the 
treatment due to complications [24]. All 4 patients suf-
fered from severe pneumonia of the treated lung that was 
followed by sepsis and finally death; 2 of them also devel-
oped abscesses surrounding some of the coils, as was evi-
Fig. 6. Coil removal. The coil placement process can be reversed to reposition or retrieve the coil. First, grasp the 
proximal ball with the forceps. After aligning the forceps and coil by slight traction, the catheter can be gently 
advanced until the end of the coil but not distally from the coil. Afterwards, the coil and catheter can be with-
drawn. Theoretically, the coil can be left at a more proximal position within the same retrieval procedure. 
Do not use the catheter to
push the guidewire forward
Do not advance the catheter
without the guidewire in front
Fig. 7. Don’ts during the coil placement. 
The most important don’t is to advance the 
catheter distally beyond the guidewire (left 
picture). The distal end of the catheter is 
too rigid and too sharp and may lead to 
haemorrhage and pneumothorax. Another 
important don’t is to use the catheter to 
push the guidewire in front (right picture). 
Allow the guidewire to do the job of finding 
the right distal bronchi. 
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dent on CT. The authors suggested that we need to fur-
ther elucidate possible aggravating factors and reduce the 
number of adverse events. 
In this respect, we recommend the following precau-
tions: 
 − careful selection of patients avoiding a high risk for 
respiratory infections; 
 − routine culture of bronchial secretions during the 
bronchoscopy procedure; 
 − a low threshold for collecting microbiological cultures 
of sputum, and starting antibiotics in case of potential 
respiratory infections after the coil placement; 
 − and a low threshold to admit patients to the hospital 
once complications after the coil placement seem to 
occur, and to instruct treated patients about this. 
Main Coil Procedure-Related Complications and 
Remarks
 − Pneumothorax 1–10%: high reported occurrence in 
the RENEW trial (12%); however, very uncommon in 
experienced sites (1%) [11]. Treatment using regular 
pneumothorax guidelines. Video-assisted thoracic 
surgery might be necessary if caused by a pleural tear 
due to inadvertent distal coil placement.
 − COPD exacerbations 10%: can be managed by regular 
care.
 − Pneumonia 10%: can be managed by regular care, be 
aware of CAO occurrence.
 − Minor haemoptysis 50%: just post-procedure up to a 
few days after a tablespoon amount of haemoptysis 
might be produced, requiring no intervention. It is 
good to inform the patient about this.
 − Major haemoptysis 1%: has been reported after treat-
ment in patients with pulmonary hypertension or 
maintenance anticoagulants (not aspirin). Manage-
ment using local guidelines.
 − CAO 10–50%: very different incidence possibly due to 
a wide variety of coil placement techniques and patient 
selection. See above for treatment guidance.
 − Avoid lung volume reduction coil treatment for pa-
tients with lifelong indications for systemic anticoagu-
lants (except aspirin/ascal/carbasalate-calcium). 
Recommended Follow-Up after the Final Coil 
Placement
3 months post-procedure:  
 − mMRC, St George’s Respiratory Questionnaire Re-
sponse (SGRQ) or other
 − Adverse events reporting
 − Physical examination
 − Chest X-ray
 − Body box and spirometry post-bronchodilator
 − Exercise testing
6 and 12 months post-procedure: 
 − mMRC, SGRQ or other
 − Adverse events reporting
 − Physical examination




• High-resolution CT scan
Recommended:
• Yearly follow-up (also in shared-care models)
• Capture all data in registries/clinical trials
Fig. 8. Coil-associated opacity. Coil-associ-
ated opacities are dense consolidations on 
the X-ray, mimicking an organizing pneu-
monia. On the left chest X-ray, the consol-
idations are in the left upper lobe, both 
proximally near the hill and distally ex-
tending to the pleura. On the right picture, 
the coil-associated opacities are larger and 
more dense. The coil-associated opacity in 
the left upper lobe shows also pleural in-
volvement. Sometimes, an extra side view 
or computed tomography scanning is nec-
essary to demonstrate the coil-associated 
position.




Disclosure Statement All authors treated patients in clinical trials, sponsored by 
PneumRx/BTG, USA. M.H., F.H., and P.S. treated patients with 
coils under regular care. All authors advised to PneumRx/BTG, 
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Box 3. Key messages
Lung volume reduction coil treatment in severe emphysema
– has an acceptable safety profile in carefully selected patients, although special awareness has to be 
present for coil-associated opacity;
– is thought to reduce lung volume by compressing the most destructed areas of the lung parenchyma and 
to restore the lung elastic recoil; however, the exact mechanism of action still has to be elucidated;
– results in an improvement in pulmonary function, exercise performance and quality of life, particularly 
in patients with severe hyperinflation (RV >200% predicted) and heterogeneous emphysema;
– is also, but less, effective in lower-lobe predominant and homogeneous emphysema;
– is independent of collateral flow and does not sacrifice the treated area of gas exchange;
– patients should be managed in a dedicated multidisciplinary team.
